Ocugen announces preliminary data from Phase 2 ArMaDa study

Ocugen (OCGN) announced preliminary 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410, its novel modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. Key findings from Phase 2 include: 46% lesion growth reduction at 12 months; Medium dose achieved 54% lesion reduction vs. high dose 36% compared to control; 50% responder rate with patients achieving greater than50% lesion size reduction vs. control; Subgroup showed 57% greater reduction in lesion size compared to control. New findings from Phase 1 include: In evaluable subjects ellipsoid zone loss was 60% slower in OCU410-treated eyes compared to untreated fellow eyes at 12 months; EZ-RPE complex loss reduced in treated eyes versus fellow eyes, demonstrating photoreceptor + RPE preservation